kabutan

CHUGAI PHARMACEUTICAL CO., LTD.(4519) Summary

4519
TSE Prime
CHUGAI PHARMACEUTICAL CO., LTD.
9,362
JPY
-67
(-0.71%)
Mar 13, 3:30 pm JST
58.73
USD
Mar 13, 2:30 am EDT
Result
PTS
outside of trading hours
9,393
Mar 13, 9:58 pm JST
Summary Chart Historical News Financial Result
PER
PBR
7.61
Yield
1.41%
Margin Trading Ratio
5.77
Stock Price
Mar 13, 2026
Opening Mar 13, 9:01 am
9,279 JPY 58.31 USD
Previous Close Mar 12
9,429 JPY 59.31 USD
High Mar 13, 10:15 am
9,478 JPY 59.57 USD
Low Mar 13, 9:01 am
9,279 JPY 58.31 USD
Volume
2,111,400
Trading Value
0.02T JPY 0.12B USD
VWAP
9340.07 JPY 58.59 USD
Minimum Trading Value
936,200 JPY 5,873 USD
Market Cap
15.72T JPY 0.10T USD
Number of Trades
4,346
Liquidity & Number of Trades
As of Mar 13, 2026
Liquidity
High
1-Year Average
7,149
1-Year High Aug 8, 2025
42,808
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 6, 2026 124,600 529,600 4.25
Feb 27, 2026 188,100 461,900 2.46
Feb 20, 2026 186,300 473,700 2.54
Feb 13, 2026 138,300 535,200 3.87
Feb 6, 2026 112,100 681,700 6.08
Company Profile
CHUGAI PHARMACEUTICAL CO., LTD. is a major pharmaceutical company. As a subsidiary of Roche, it has expanded its product line, including Tamiflu. The company's main focus is on anticancer drugs and rheumatoid arthritis treatments.
Sector
Pharmaceuticals
CHUGAI PHARMACEUTICAL CO., LTD. is a pharmaceutical company specializing in the research, development, manufacturing, and sales of pharmaceuticals, operating under the Swiss pharmaceutical giant Roche. In Japan, the company sells its own products through authorized dealers, while overseas it has sales bases in Europe, Taiwan, China, and other regions. Manufacturing is carried out at the company's domestic and international factories, as well as through contracted partners. As a member of the Roche Group, Chugai purchases some raw materials from Roche and distributes some products internationally through Roche's network. The company focuses on developing innovative drugs, particularly in the fields of cancer treatment and rheumatoid arthritis, while pursuing global business expansion.